CF
SWTX

Corebridge Financial’s SpringWorks Therapeutics SWTX Stock Holding History

Corebridge Financial’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-33,678
Closed -$1.49M – 2469
2025
Q1 		$1.49M Sell
33,678
-500
-1% -$23K 0.01% 1102
2024
Q4 		$1.23M Sell
34,178
-2,579
-7% -$90.1K 0.01% 1238
2024
Q3 		$1.18M Sell
36,757
-227
-0.6% -$8.48K 0.01% 1278
2024
Q2 		$1.39M Buy
+36,984
New +$1.56M 0.01% 1162

Other funds holding SWTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

Corebridge Financial's SWTX Position: Q2 2025 in Review

Corebridge Financial sold out of SpringWorks Therapeutics (SWTX) in Q2 2025, closing a stake of 33,678 shares — an estimated $1.49M sold.

Corebridge Financial first reported a position in SWTX in Q2 2024 and held it in 4 quarters. The position peaked at $1.49M in Q1 2025. 223 funds tracked by Wall St. Rank hold SWTX as of Q2 2025.

  • Corebridge Financial reported no remaining SpringWorks Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 33,678 SpringWorks Therapeutics shares in Q2 2025, an estimated $1.49M.
  • Corebridge Financial first reported a position in SpringWorks Therapeutics in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's SpringWorks Therapeutics position peaked at $1.49M in Q1 2025.
  • 223 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.